IpragliflozinIpragliflozin (INN, trade names Suglat) is a pharmaceutical drug for treatment of type 2 diabetes. Ipragliflozin, jointly developed by Astellas Pharma and Kotobuki Pharmaceutical, was approved in Japan on January 17, 2014, and in Russia on May 22, 2019. Read from the Drugbox of the Wikipedia article Ipragliflozin, revision 1370302319.

Property

Value

Formula

C21H21FO5S, 404.46 g/mol

Bioavailability

90.2 %

Protein binding

95.55 %

Elimination half-life

14.97 h

The compounds of every Wikipedia article carrying a Chembox or a Drugbox, refreshed daily, with the values their infoboxes give. The pages need JavaScript; the API does not.